Jonathan MacQuitty focuses on life science and healthcare investments. He was formerly a partner at Abingworth, a trans-Atlantic life science venture capital firm, heading up the firm’s West Coast office.
Since May 2015, he has been the initial CEO of Forty Seven Inc. Forty Seven is a Lightspeed portfolio company developing immuno-oncology therapeutics to treat various cancers. The technology was licensed out of Stanford University in 2015. The company’s lead product is currently in two different clinical studies. Jonathan is also Chairman of Personalis, another Lightspeed portfolio company which is commercializing human genomic analysis for cancer research and diagnosis.
Jonathan has spent over 30 years in life science companies and in the venture capital sector that finances them. He joined Abingworth in 1999 as President of the firm’s US subsidiary based in Menlo Park, CA. Between1988 until its acquisition in 1997, he was CEO of GenPharm International, a Bay Area biotech company developing a human sequence antibody platform. Prior to that he held business development positions at Genencor and Genentech.
His directorships have included Acorda (now NASDAQ), Dicerna (now NASDAQ), Guava (acquired), Gynesonics, Labcyte, Myelos (acquired), Palo Alto Health Sciences, ParAllele BioScience (acquired), Quantum Dot (acquired), SFJ Pharma, Sosei (now listed in Tokyo), and Sunesis (now NASDAQ).
He has also served on the Board of the Biotechnology Industry Organization (BIO).
Jonathan has an MA in Chemistry from Oxford University, a PhD in Chemistry from the University of Sussex, and an MBA from Stanford University.